The FDA on November 9, 2017 granted regular approval to ADCETRIS®, for the treatment of adult patients with primary cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-expressing Mycosis Fungoides (MF), who have received prior systemic therapy. ADCETRIS® is a product of Seattle Genetics, Inc.
Bottom Ad
Advertisement
Subscribe
